ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB today announced new Cimzia® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms and pain for patients, as well as results of a survey showing the impact of RA pain on the daily lives of women, focusing on productivity and relationships, during the 2010 European League Against Rheumatism (EULAR) annual congress in Rome, Italy, June 16-19. "Insights from these data help us better understand the true impact of living with RA," said Vibeke Strand, M.D., Adjunct Clinical Professor, Division of Immunology and Rheumatology, at Stanford University, California, and lead author of the Good Days and FAST4WARD studies.
Horizon Pharma Announces LODOTRA(R) and DUEXA(R) Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRA®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy, June 16-19.
Ardea Biosciences to Present Additional Data on Gout Program at the Annual European Congress of Rheumatology
SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present additional data from its completed Phase 2a and Phase 2b monotherapy studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy on June 18th and 19th.
